{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:18:12Z","timestamp":1770747492162,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.amjcard.2009.11.044","type":"journal-article","created":{"date-parts":[[2010,2,6]],"date-time":"2010-02-06T09:25:45Z","timestamp":1265448345000},"page":"849-852","source":"Crossref","is-referenced-by-count":19,"title":["Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases"],"prefix":"10.1016","volume":"105","author":[{"given":"Steven G.","family":"Chrysant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2009.11.044_bib1","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/hj.1998.v135.86971","article-title":"Vascular remodeling: the role of angiotensin-converting enzyme inhibitors","volume":"135","author":"Chrysant","year":"1998","journal-title":"Am Heart J"},{"issue":"suppl","key":"10.1016\/j.amjcard.2009.11.044_bib2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/01.hjh.0000165623.72310.dd","article-title":"The cardiovascular continuum and renin-angiotensin-aldosterone blockade","volume":"23","author":"Dzau","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0002-9343(72)90054-X","article-title":"Renin, angiotensin and aldosterone system in the pathogenesis and management of hypertensive vascular disease","volume":"52","author":"Vaughn","year":"1972","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/HYPERTENSIONAHA.108.116350","article-title":"Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure","volume":"52","author":"Westermann","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/01.HYP.25.4.474","article-title":"Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension","volume":"25","author":"Thybo","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction (LIFE) in hypertension: a randomized trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.11.044_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.11.044_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":"Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib9","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2009.11.044_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00004872-199208000-00015","article-title":"Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response?","volume":"10","author":"Van Den Meiracker","year":"1992","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2005.02.016","article-title":"Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition","volume":"26","author":"Van De Wal","year":"2006","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2009.11.044_bib12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00005344-199002000-00015","article-title":"Reactive hyper-reninemia is a major determinant of plasma angiotensin II during ACE inhibition","volume":"15","author":"Mooser","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.amjcard.2009.11.044_bib13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00392-008-0668-3","article-title":"RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection","volume":"97","author":"Werner","year":"2008","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2009.11.044_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/01.HYP.29.2.634","article-title":"Additive effects of losartan and enalapril on blood pressure and plasma active renin","volume":"29","author":"Azizi","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1524-6175.2005.05264.x","article-title":"The pleiotropic effects of angiotensin receptor blockers","volume":"8","author":"Chrysant","year":"2006","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib17","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study","volume":"21","author":"Mogensen","year":"2000","journal-title":"Br J Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1524-6175.2004.03511.x","article-title":"Antihypertensive efficacy of candesartan-lisinopril in combination vs uptitration of lisinopril: the AMAZE trials","volume":"6","author":"Izzo","year":"2004","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/01.HYP.0000161880.59963.da","article-title":"Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension","volume":"45","author":"Doulton","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjhyper.2006.06.003","article-title":"Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan","volume":"20","author":"Pool","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.11.044_bib23","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1185\/030079908X280581","article-title":"Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis","volume":"24","author":"Chrysant","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjcard.2009.11.044_bib24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination of angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2009.11.044_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2009.11.044_bib27","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/01.HYP.0000047512.58862.A9","article-title":"Angiotensin II receptor blockade","volume":"41","author":"Forclaz","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2009.11.044_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archfami.5.1.17","article-title":"Effects of benazepril and hydrochlorothiazide, given alone and in low-and high-dose combinations, on blood pressure in patients with hypertension","volume":"5","author":"Chrysant","year":"1996","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.amjcard.2009.11.044_bib30","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH: a randomized double-blind, placebo-controlled, 8-week factorial efficacy and safety study","volume":"30","author":"Chrysant","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.amjcard.2009.11.044_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2009.11.044_bib32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2008.10.036","article-title":"The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate endpoint","volume":"53","author":"Messerli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2009.11.044_bib33","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.108.821512","article-title":"Leapfrogging data: no shortcuts for safety or efficacy information","volume":"118","author":"Pfeffer","year":"2008","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909027702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914909027702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T11:54:46Z","timestamp":1544702086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914909027702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0002914909027702"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2009.11.044","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}